A week-by-week breakdown of the semaglutide research timeline — from first-dose appetite suppression through the rapid weight loss phase to maximum effect at 68 weeks, based on STEP trial data.
GLP-1 receptors in the hypothalamus begin responding within 24–48 hours of the first dose. Most researchers report reduced hunger and earlier satiety by day 3–5. Nausea is most common in this phase — it typically peaks at week 1–2 and subsides as the body adapts.
Most researchers see 1–3 kg of weight loss by week 4 at the starting dose (0.25 mg/week). This early loss is partly water weight from reduced carbohydrate intake due to appetite suppression. Gastric emptying slows noticeably — meals feel more filling with smaller portions.
The dose increases to 0.5 mg/week at week 5. Weight loss accelerates to 0.5–1 kg/week in most subjects. Nausea typically resolves by week 6–8. Energy levels may temporarily dip as caloric intake decreases — this is normal and resolves within 2–4 weeks.
At 1 mg/week (reached at week 13 in the standard titration), weight loss is typically 1–2% of body weight per month. This is the most productive phase. Researchers in STEP 1 lost an average of 8–10% of body weight by week 24.
Weight loss continues but slows as the body adapts. The 2.4 mg/week dose (maximum) is typically reached around week 17. Maximum weight loss of ~15% is achieved at week 68 in STEP 1. Some subjects plateau earlier and may benefit from dose optimization.
STEP 4 extension data shows that subjects who stop semaglutide regain ~2/3 of lost weight within 1 year. This is a class effect of GLP-1 agonists — the underlying metabolic drivers of obesity are not permanently resolved. Maintenance dosing or transition to a higher-generation compound is typically needed.
| Milestone | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Appetite suppression onset | Days 3–5 | Days 3–5 | Days 3–5 |
| First measurable weight loss | Week 2–4 | Week 2–4 | Week 2–4 |
| Rapid loss phase | Weeks 4–24 | Weeks 4–24 | Weeks 4–24 |
| Mean weight loss at 24 weeks | ~8% | ~14% | ~17% |
| Maximum weight loss | ~15% (wk 68) | ~22% (wk 72) | ~24% (wk 48) |
| Time to max dose | 17 weeks | 20 weeks | 12 weeks |
All three compounds have similar onset timelines. The key difference is the ceiling — retatrutide and tirzepatide produce significantly greater maximum weight loss due to additional receptor mechanisms.
Appetite suppression begins within the first week. Measurable weight loss (1–3 kg) typically occurs within 4 weeks. The most rapid weight loss phase is between weeks 4–24. Maximum weight loss (~15% of body weight) is achieved at approximately 68 weeks in clinical trials.
Appetite suppression typically begins within 24–48 hours of the first dose. Most subjects report reduced hunger and earlier satiety by day 3–5. The appetite-suppressing effect is present throughout the dosing interval (7 days) due to semaglutide's long half-life.
Common reasons include: still in the titration phase (full effect requires reaching the therapeutic dose of 1–2.4 mg/week), compensatory eating behaviors, insufficient caloric deficit despite appetite suppression, or individual variation in GLP-1 receptor sensitivity. Some subjects require dose optimization or transition to tirzepatide or retatrutide for greater effect.
Semaglutide has a half-life of approximately 7 days. After stopping, it takes approximately 5–7 half-lives (5–7 weeks) to clear the system. Appetite typically returns within 2–4 weeks of stopping.
Higher doses produce greater weight loss but not necessarily faster onset. The titration schedule exists to minimize GI side effects — skipping titration steps causes significant nausea and vomiting. The therapeutic dose range of 1–2.4 mg/week produces the most weight loss, but the timeline to maximum effect is similar regardless of final dose.
Purgo Labs provides pharmaceutical-grade semaglutide with third-party COAs. Use code HEALTH for 15% off your first order.
Buy Semaglutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.